TN-001
TN-001 is a non-hallucinogenic psychoplastogen which is under development for the treatment of major depressive disorder and post-traumatic stress disorder. Its route of administration is unspecified. The drug acts as a serotonin receptor modulator, including as a serotonin 5-HT2A receptor partial agonist and serotonin 5-HT2B receptor antagonist, and has been found to produce psychoplastogenic effects without inducing the head-twitch response. It is being developed by Transneural Therapeutics, a spinout of CaaMTech. As of June 2025, TN-001 is in the preclinical research stage of development. A clinical trial is being planned. The chemical structure of the drug does not yet appear to have been disclosed.